• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

以及幕上室管膜瘤的建模系统。

and modeling systems of supratentorial ependymomas.

作者信息

Hatanaka Emily A, Breunig Joshua J

机构信息

Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.

Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States.

出版信息

Front Oncol. 2024 Feb 26;14:1360358. doi: 10.3389/fonc.2024.1360358. eCollection 2024.

DOI:10.3389/fonc.2024.1360358
PMID:38469231
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10925685/
Abstract

Ependymomas are rare brain tumors that can occur in both children and adults. Subdivided by the tumors' initial location, ependymomas develop in the central nervous system in the supratentorial or infratentorial/posterior fossa region, or the spinal cord. Supratentorial ependymomas (ST-EPNs) are predominantly characterized by common driver gene fusions such as and fusions. Some variants of ST-EPNs carry a high overall survival rate. In poorly responding ST-EPN variants, high levels of inter- and intratumoral heterogeneity, limited therapeutic strategies, and tumor recurrence are among the reasons for poor patient outcomes with other ST-EPN subtypes. Thus, modeling these molecular profiles is key in further studying tumorigenesis. Due to the scarcity of patient samples, the development of preclinical and models that recapitulate patient tumors is imperative when testing therapeutic approaches for this rare cancer. In this review, we will survey ST-EPN modeling systems, addressing the strengths and limitations, application for therapeutic targeting, and current literature findings.

摘要

室管膜瘤是一种罕见的脑肿瘤,可发生于儿童和成人。根据肿瘤的初始位置细分,室管膜瘤发生于中枢神经系统的幕上或幕下/后颅窝区域,或脊髓。幕上室管膜瘤(ST-EPNs)主要特征为常见的驱动基因融合,如 和 融合。ST-EPNs的一些变体总体生存率较高。在反应较差的ST-EPN变体中,肿瘤间和肿瘤内高度异质性、有限的治疗策略以及肿瘤复发是导致患者预后比其他ST-EPN亚型差的原因之一。因此,模拟这些分子特征是进一步研究肿瘤发生的关键。由于患者样本稀缺,在测试这种罕见癌症的治疗方法时,开发能够重现患者肿瘤的临床前 和 模型势在必行。在本综述中,我们将概述ST-EPN建模系统,探讨其优势和局限性、治疗靶点应用以及当前文献研究结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0af/10925685/33a8836473db/fonc-14-1360358-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0af/10925685/33a8836473db/fonc-14-1360358-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0af/10925685/33a8836473db/fonc-14-1360358-g001.jpg

相似文献

1
and modeling systems of supratentorial ependymomas.以及幕上室管膜瘤的建模系统。
Front Oncol. 2024 Feb 26;14:1360358. doi: 10.3389/fonc.2024.1360358. eCollection 2024.
2
Supratentorial and Infratentorial Ependymoma.幕上和幕下室管膜瘤。
Adv Tech Stand Neurosurg. 2024;53:93-118. doi: 10.1007/978-3-031-67077-0_7.
3
C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin.C11orf95-RELA 融合和 NF-κB 信号的上调特征是表达 L1CAM 和巢蛋白的侵袭性幕上室管膜瘤亚群的特征。
J Neurooncol. 2018 May;138(1):29-39. doi: 10.1007/s11060-018-2767-y. Epub 2018 Jan 22.
4
A coordinated approach for the assessment of molecular subgroups in pediatric ependymomas using low-cost methods.采用低成本方法评估小儿室管膜瘤分子亚群的协调方法。
J Mol Med (Berl). 2021 Aug;99(8):1101-1113. doi: 10.1007/s00109-021-02074-2. Epub 2021 Apr 26.
5
Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.室管膜瘤分子分类的意义:C11orf95-RELA 融合阴性幕上室管膜瘤是一组异质性肿瘤。
Acta Neuropathol Commun. 2018 Dec 4;6(1):134. doi: 10.1186/s40478-018-0630-1.
6
Identification of HDAC4 as a potential therapeutic target and prognostic biomarker for ZFTA-fused ependymomas.鉴定 HDAC4 作为 ZFTA 融合性室管膜瘤的潜在治疗靶点和预后生物标志物。
Cancer Gene Ther. 2023 Aug;30(8):1105-1113. doi: 10.1038/s41417-023-00616-z. Epub 2023 Apr 11.
7
Molecular profiling of pediatric and adolescent ependymomas: identification of genetic variants using a next-generation sequencing panel.儿童和青少年室管膜瘤的分子分析:使用下一代测序面板鉴定遗传变异。
J Neurooncol. 2021 Oct;155(1):13-23. doi: 10.1007/s11060-021-03848-x. Epub 2021 Sep 27.
8
Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome.室管膜瘤综述:病理诊断共识评估及与基因谱和预后的相关性。
Brain Tumor Pathol. 2019 Apr;36(2):92-101. doi: 10.1007/s10014-019-00338-x. Epub 2019 Mar 30.
9
Molecular subtyping of ependymoma and prognostic impact of Ki-67.室管膜瘤的分子亚型与 Ki-67 的预后影响。
Brain Tumor Pathol. 2022 Jan;39(1):1-13. doi: 10.1007/s10014-021-00417-y. Epub 2021 Nov 23.
10
Ependymal Tumors: Overview of the Recent World Health Organization Histopathologic and Genetic Updates with an Imaging Characteristic.室管膜肿瘤:近期世界卫生组织组织病理学和遗传学更新的概述,包括影像学特征。
AJNR Am J Neuroradiol. 2024 Nov 7;45(11):1624-1634. doi: 10.3174/ajnr.A8237.

本文引用的文献

1
Patient- and xenograft-derived organoids recapitulate pediatric brain tumor features and patient treatments.患者和异种移植物衍生类器官重现了儿科脑肿瘤的特征和患者的治疗情况。
EMBO Mol Med. 2023 Dec 7;15(12):e18199. doi: 10.15252/emmm.202318199. Epub 2023 Nov 30.
2
Human Patient-Derived Brain Tumor Models to Recapitulate Ependymoma Tumor Vasculature.用于概括室管膜瘤肿瘤血管系统的人源患者脑肿瘤模型
Bioengineering (Basel). 2023 Jul 15;10(7):840. doi: 10.3390/bioengineering10070840.
3
A clinicopathological analysis of supratentorial ependymoma, ZFTA fusion-positive: utility of immunohistochemical detection of CDKN2A alterations and characteristics of the immune microenvironment.
幕上室管膜瘤,ZFTA 融合阳性的临床病理分析:免疫组化检测 CDKN2A 改变的效用和免疫微环境特征。
Brain Tumor Pathol. 2023 Jul;40(3):163-175. doi: 10.1007/s10014-023-00464-7. Epub 2023 Jun 16.
4
Identification of HDAC4 as a potential therapeutic target and prognostic biomarker for ZFTA-fused ependymomas.鉴定 HDAC4 作为 ZFTA 融合性室管膜瘤的潜在治疗靶点和预后生物标志物。
Cancer Gene Ther. 2023 Aug;30(8):1105-1113. doi: 10.1038/s41417-023-00616-z. Epub 2023 Apr 11.
5
Prime editing for precise and highly versatile genome manipulation.碱基编辑技术实现精准且多功能的基因组编辑。
Nat Rev Genet. 2023 Mar;24(3):161-177. doi: 10.1038/s41576-022-00541-1. Epub 2022 Nov 7.
6
Activation of Hedgehog signaling by the oncogenic RELA fusion reveals a primary cilia-dependent vulnerability in supratentorial ependymoma.致癌 RELA 融合蛋白激活 Hedgehog 信号通路揭示幕上室管膜瘤中存在原发性纤毛依赖性脆弱性。
Neuro Oncol. 2023 Jan 5;25(1):185-198. doi: 10.1093/neuonc/noac147.
7
Ependymoma: Evaluation and Management Updates.室管膜瘤:评估与管理的最新进展。
Curr Oncol Rep. 2022 Aug;24(8):985-993. doi: 10.1007/s11912-022-01260-w. Epub 2022 Apr 6.
8
Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy.克服将 CRISPR/Cas9 用作癌症治疗替代方法的主要挑战的策略。
Mol Cancer. 2022 Mar 3;21(1):64. doi: 10.1186/s12943-021-01487-4.
9
The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer.Hippo 通路与癌症:YAP/TAZ 和 TEAD 作为癌症治疗靶点。
Clin Sci (Lond). 2022 Feb 11;136(3):197-222. doi: 10.1042/CS20201474.
10
CRISPR-Cas9 induces large structural variants at on-target and off-target sites in vivo that segregate across generations.CRISPR-Cas9 在体内诱导靶向和非靶向位点的大结构变体,这些变体在代际间分离。
Nat Commun. 2022 Feb 2;13(1):627. doi: 10.1038/s41467-022-28244-5.